Early-onset muscular dystrophy presents unique challenges that could reshape how clinicians approach one of the most common inherited muscle disorders. When facioscapulohumeral dystrophy strikes children rather than teenagers, the disease trajectory and management needs differ substantially from typical adult presentations. This comprehensive clinical review synthesizes current understanding of childhood-onset FSHD, examining how genetic mechanisms translate into distinct symptom patterns in pediatric populations. The analysis reveals that early manifestation cases often present more severe progression rates and require modified diagnostic criteria compared to standard adolescent or adult onset. Key findings highlight specific muscle involvement patterns unique to childhood cases, with facial and shoulder-blade muscles showing accelerated weakness that can significantly impact developmental milestones and quality of life. The research consolidates evidence on multidisciplinary treatment approaches specifically tailored for younger patients, addressing both physical rehabilitation and psychosocial support needs. Perhaps most significantly, this work establishes frameworks for including pediatric FSHD patients in emerging clinical trials, a critical step as experimental therapies targeting the underlying DUX4 gene expression pathway advance toward human testing. The comprehensive review addresses a notable gap in pediatric neuromuscular medicine, where childhood-onset FSHD has historically received less research attention despite representing a distinct clinical entity. For families navigating early diagnosis, this synthesis provides evidence-based guidance on optimal care coordination and realistic prognostic expectations, while laying groundwork for future therapeutic interventions specifically designed for developing patients.